Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Kiniksa Pharmaceuticals, Ltd. | knsa-20191231x10k.htm |
| EX-32.2 - EX-32.2 - Kiniksa Pharmaceuticals, Ltd. | knsa-20191231ex3222b0d12.htm |
| EX-32.1 - EX-32.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20191231ex321d2daa2.htm |
| EX-31.2 - EX-31.2 - Kiniksa Pharmaceuticals, Ltd. | knsa-20191231ex312dbcb90.htm |
| EX-31.1 - EX-31.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20191231ex311b0ab26.htm |
| EX-10.25 - EX-10.25 - Kiniksa Pharmaceuticals, Ltd. | knsa-20191231ex102510fda.htm |
| EX-10.24 - EX-10.24 - Kiniksa Pharmaceuticals, Ltd. | knsa-20191231ex1024a4271.htm |
| EX-4.3 - EX-4.3 - Kiniksa Pharmaceuticals, Ltd. | knsa-20191231ex432cb0dd4.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-231910) and Form S-8 (No. 333-225196) of Kiniksa Pharmaceuticals, Ltd. of our report dated March 5, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 5, 2020